These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Transdermal scopolamine for motion sickness. Med Lett Drugs Ther; 1981 Oct; 23(21):89-90. PubMed ID: 7027000 [No Abstract] [Full Text] [Related]
3. Transdermal scopolamine: a review of its effects upon motion sickness, psychological performance, and physiological functioning. Parrott AC Aviat Space Environ Med; 1989 Jan; 60(1):1-9. PubMed ID: 2647072 [TBL] [Abstract][Full Text] [Related]
4. Histaminergic response to Coriolis stimulation: implication for transdermal scopolamine therapy of motion sickness. Wang ET; Zhou DR; He LH Aviat Space Environ Med; 1992 Jul; 63(7):579-82. PubMed ID: 1616432 [TBL] [Abstract][Full Text] [Related]
5. Transdermal scopolamine in the prevention of motion sickness: evaluation of the time course of efficacy. Homick JL; Kohl RL; Reschke MF; Degioanni J; Cintron-Trevino NM Aviat Space Environ Med; 1983 Nov; 54(11):994-1000. PubMed ID: 6651736 [TBL] [Abstract][Full Text] [Related]
6. The Republic of Singapore Navy's Scopoderm TTS study: results after 2,200 man-days at sea. How J; Lee PS; Seet LC; Tan PK Aviat Space Environ Med; 1988 Jul; 59(7):646-50. PubMed ID: 3044323 [TBL] [Abstract][Full Text] [Related]
7. Comparison of the effects of a selective muscarinic receptor antagonist and hyoscine (scopolamine) on motion sickness, skin conductance and heart rate. Golding JF; Stott JR Br J Clin Pharmacol; 1997 Jun; 43(6):633-7. PubMed ID: 9205824 [TBL] [Abstract][Full Text] [Related]
8. Transdermal scopolamine intoxication in a child. Klein BL; Ashenburg CA; Reed MD Pediatr Emerg Care; 1985 Dec; 1(4):208-9. PubMed ID: 3842169 [No Abstract] [Full Text] [Related]
9. Intramuscular hyoscine in control of motion sickness. Brand JJ; Whittingham P Lancet; 1970 Aug; 2(7666):232-4. PubMed ID: 4193688 [No Abstract] [Full Text] [Related]
10. Transderm scopolamine efficacy related to time of application prior to the onset of motion. Levy GD; Rapaport MH Aviat Space Environ Med; 1985 Jun; 56(6):591-3. PubMed ID: 4015572 [TBL] [Abstract][Full Text] [Related]
11. Treatment of severe motion sickness with antimotion sickness drug injections. Graybiel A; Lackner JR Aviat Space Environ Med; 1987 Aug; 58(8):773-6. PubMed ID: 3632537 [TBL] [Abstract][Full Text] [Related]
12. Transdermal scopolamine delivery system (TRANSDERM-V) and acute angle-closure glaucoma. Hamill MB; Suelflow JA; Smith JA Ann Ophthalmol; 1983 Nov; 15(11):1011-2. PubMed ID: 6651138 [TBL] [Abstract][Full Text] [Related]
13. Three-years' experience of transdermal scopolamine: long-term effectiveness and side-effects. Shupak A; Gordon CR; Spitzer O; Mendelowitz N; Melamed Y Pharmatherapeutica; 1989; 5(6):365-70. PubMed ID: 2594820 [TBL] [Abstract][Full Text] [Related]
14. Accidental mydriasis from scopolamine patches. Rosen NB J Am Optom Assoc; 1986 Jul; 57(7):541-2. PubMed ID: 3745760 [TBL] [Abstract][Full Text] [Related]
16. The effects of TTS-scopolamine, dimenhydrinate, lidocaine, and tocainide on motion sickness, vertigo, and nystagmus. Pyykkö I; Padoan S; Schalén L; Lyttkens L; Magnusson M; Henriksson NG Aviat Space Environ Med; 1985 Aug; 56(8):777-82. PubMed ID: 3929760 [TBL] [Abstract][Full Text] [Related]
17. Acupressure and motion sickness. Bruce DG; Golding JF; Hockenhull N; Pethybridge RJ Aviat Space Environ Med; 1990 Apr; 61(4):361-5. PubMed ID: 2339974 [TBL] [Abstract][Full Text] [Related]